Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCD, FRANKFURT: HBP0), a clinical-stage oncology company, has announced immediate changes to its Board of Directors. Janusz Grabski has resigned from the Board, and Thomas Mehrling, M.D., Ph.D., who serves as Helix's Chief Executive Officer, has been appointed as a director. This appointment is made pursuant to the board nomination right granted to Laevoroc Immunology AG in connection with Helix's 2025 acquisition of substantially all of the assets of Laevoroc Immunology AG and Laevoroc Chemotherapy AG.
The company states that these changes are intended to ensure the Board continues to meet Helix's evolving governance and capital markets requirements, and has the composition and experience needed to support the Company's clinical development and broader corporate objectives. The Board expressed gratitude to Mr. Grabski for his service and contributions, wishing him success in his future endeavors.
Helix BioPharma is focused on developing therapies for underserved patient populations with difficult-to-treat cancers. Its lead pipeline candidate is L-DOS47, a clinical-stage antibody-enzyme conjugate being developed as a combination therapy for non-small cell lung cancer (NSCLC). Additional candidates include LEUMUNA™, a pre-IND oral immune checkpoint modulator for post-transplant leukemia relapse, and GEMCEDA™, a pre-IND gemcitabine prodrug for advanced solid tumors. The company's common shares are listed on the Toronto Stock Exchange (TSX: HBP), quoted on the OTC Pink Market (HBPCD), and listed on the Frankfurt Stock Exchange (FWB: HBP0).
These board changes come at a pivotal time for Helix as it advances its clinical programs and integrates assets from the Laevoroc acquisition. The addition of Dr. Mehrling to the board may align leadership with the company's strategic direction, potentially facilitating smoother decision-making and stronger oversight of its pipeline. This move could help reassure investors about the company's governance as it progresses towards clinical milestones.
For more information about Helix BioPharma and its pipeline, interested parties can visit the company's website at https://www.helixbiopharma.com/. Additional context on the Laevoroc acquisition can be found at Helix's announcement regarding the acquisition.
